Breaking

Send us your questions for economist Isabella Weber on inflation and affordability DHS officials defend their actions in shooting of NYC immigrant amid outcry AI surveillance startup Flock to cut several hundred jobs amid backlash, sources say Controversial vaccine trial touted by RFK Jr gets go-ahead in Guinea-Bissau State Department IG probing Kimberly Guilfoyle amid alleged $100,000 demand Afrobeats singer Ayra Starr on making history at her NFL half-time show Anthropic can’t reliably control its AI agents. It’s cutting off its internal evals from the live internet instead US country music star Ella Langley cancels show due to 'security threat' ‘Franchise cricket isn’t as rewarding’: Jonathan Trott on Lions pride and England ambitions Wales hope pattern continues in Albania return

NEWSREEL

The day, in 30-second reels.

--:--:--

Science / Reel

Science · Video brief

Controversial vaccine trial touted by RFK Jr gets go-ahead in Guinea-Bissau

A controversial trial to withhold hepatitis B vaccines from newborns has been approved in Guinea-Bissau, enrolling 14,000 infants. Despite international backlash and ethical concerns, the study will compare vaccinated and unvaccinated group...

The Guardian· Oct 10, 2026 · 12:19 PM · 3 views

Video won't play? Watch on YouTube →

A controversial trial to withhold hepatitis B vaccines from newborns has been approved in Guinea-Bissau, enrolling 14,000 infants. Despite international backlash and ethical concerns, the study will compare vaccinated and unvaccinated groups.

Full story and more reels: https://newsreel.video #news #breaking #vaccine #health #GuineaBissau #ethics #research

Originally reported by The Guardian. Read the full story →

More in Science

Elon Musk’s growing SpaceX empire sends AT&T, Verizon and T-Mobile shares plunging

NBC News· 2 hours ago

Climate crisis is coming to crush many of world’s best surf breaks, study warns

The Guardian· 2 hours ago

What happens when you grow up not knowing your family medical history?

BBC News· 2 hours ago

0 Comments

No comments yet. Be the first.